This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.FacultyJeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.Related episode...

This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:Compares traditional ultrasound with advanced imaging techniques.Examines AI-based approaches in patient classification.The episode concludes with a forward-looking perspective on the future management ...

Renal dysfunction is a significant concern for patients with liver cirrhosis, affecting nearly 50% of those hospitalised and leading to various complications that can reduce survival rates. Recently, the diagnostic criteria for acute kidney injury (AKI) and hepatorenal syndrome (HRS) have been updated to better capture the diversity and incidence of these conditions in cirrhotic patients.This episode of EASL Studio:Explores the updated definitions and standardisation of AKI in the context of ...

EASL Studio - SLD nomenclature: Need for refinement?FacultyAleksander Krag (Moderator)Meena Bansal (Faculty)Sven Francque (Faculty)Alexandre Louvet (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Landmark studies at the EASL Congress 2024FacultyThomas Berg (Moderator)Rajiv Jalan (Faculty)Verena Keitel (Faculty)Frank Tacke (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Exploring new frontiers: The AI liver taskforce initiativeFacultyEric Trépo (Moderator)Tom Lüdde (Faculty)Jakob Kather (Faculty)Raquel Pérez-López (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Education at the heart of EASL’s missionFacultySven Francque (Moderator)Krista Rombouts (Faculty)Rajeshwar Mookerjee (Faculty)Henning Grønbæk (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Buongiorno Milano: What not to miss during EASL Congress.FacultyAleksander Krag (Moderator)Debbie Shawcross (Faculty)Thomas Berg (Faculty)Ahmed Elsharkawy (Faculty)All EASL Studio Podcasts are available on EASL Campus.

Arrivederci Milano, hallo Amsterdam!FacultyAleksander Krag (Moderator)Debbie Shawcross (Moderator)Cyrielle Caussy (Faculty)Ana Lleo (Faculty)Francesco Negro (Faculty)Vlad Ratziu (Faculty)Virginia Hernández-Gea (Faculty)All EASL Studio Podcasts are available on EASL Campus.

EASL Studio - Advances in systemic treatments in liver cancerFacultyJosep Llovet (Moderator)Massimo Iavarone (Faculty)Matthias Pinter (Faculty)Jessica Zucman-Rossi (Faculty)All EASL Studio Podcasts are available on EASL Campus.

This session covers a wide range of topics relevant to the current landscape of viral hepatitis, including elimination efforts, resistance to direct-acting antivirals (DAAs), surveillance methods during and after therapy. This talk provides you with valuable insights through an up-to-date overview of the latest developments and challenges in the field.FacultyThomas Berg (Moderator)Jordan Feld (Faculty)Norah Terrault (Faculty)Heiner Wedemeyer (Faculty)This episode is scheduled in honour of the...

This insightful discussion is centred on the burgeoning field of endohepatology, where advanced endoscopic techniques revolutionise hepatology practice. With this episode, explore the broad scope of endoscopic procedures (including EUS-guided liver biopsy, portal pressure measurement, and gastric varices embolisation) and their transformative impact on diagnostics and therapeutic interventions in liver disease.To learn even more about endoscopic procedures in hepatology, take a look at this s...

This episode explores the approval of resmetirom for NASH, analysing its integration into clinical practice and patient eligibility. The experts also discuss the role of lifestyle interventions alongside resmetirom, the use of biomarkers for patient selection, treatment monitoring, and the expected landscape changes over the next five years.FacultyAleksander Krag (Moderator)Naim Alkhouri (Faculty)Sven Francque (Faculty)Amalia Gastaldelli (Faculty)Related episodesSeason 5 , Episode 2: Are 30% ...

Join us for a critical discussion on the significance of Drug and Herbal & Dietary Supplement-Induced Liver Injury (DHILI). In this episode, the speakers explore the importance of DHILI, assess recent advancements, and deliberate on the obstacles hindering further progress in addressing this pressing healthcare concern.This episode is organised in collaboration with the EASL DHILI Consortium.FacultyGuruprasad Padur Aithal (Moderator)Paul Hayashi (Faculty)Maribel Lucena (Faculty)Paul Watki...

In this episode, experts explore the shift away from invasive measurements in assessing clinically significant portal hypertension. The speakers address the crucial data needed to enhance the reliability and applicability of these non-invasive methods and introduce several advanced elastography techniques, shaping the future of portal hypertension assessment.FacultyBogdan Procopet (Moderator)Maria Papp (Faculty)Atoosa Rabiee (Faculty)Thomas Reiberger (Faculty)Related episodeEASL Studio S2E14:...

This episode aims at highlighting the importance of patient and public involvement in research. More precisely, the speakers focus on the importance of involving patients in research, practical steps to involve patients in research, and insights from EASL including engagement of patients in the EASL-Lancet Commission. Faculty Marta Alonso-Peña (Moderator)Kate Jack (Faculty)Marko Korenjak (Faculty)Thomas Marjot (Faculty)Related episode EASL Studio from EASL Congress 2023: United we stand:...

This episode centres around an article recently published in the Journal of Hepatology, presenting a new treatment algorithm positioned as an evolution of the BCLC system and aimed at addressing its limitations in the staging and therapy hierarchy for HCC. This discussion covers the implications of this fresh approach in the management of HCC patients, challenging the standard paradigm. Faculty Bruno Sangro (Moderator)Umberto Cillo (Faculty) Helen Reeves (Faculty)María Reig (Faculty)This EASL...

In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs. Faculty Debbie Shawcross (Moderator)Rajiv Jalan (Faculty)Sara Montagnese (Faculty)Elliot Tapper...

This episode treats of the Hepahealth II study, which aimed at estimating the impact of policy interventions targeting alcohol and obesity on the incidence of chronic liver disease and primary liver cancer in three European countries. Join our experts in their discussion of this study and of its conclusions. Faculty Patrizia Burra (Moderator)Maria Buti (Faculty)Peter Jepsen (Faculty)Shira Zelber-Sagi (Faculty)Related episodes EASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio...

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field. Faculty Aleksander Krag (Moderator)Aftab Ala (Faculty)Pavel Strnad (Faculty)Alice Turner (Faculty)Related episodes EASL Studio from EASL Congress 2023: Clinical trials in rare diseases...

The definition of cACLD is now strongly linked to care and research outcomes such as non invasive diagnosis, reversibility and prevention of decompensation. Thus, what space is left for the use of the old term cirrhosis in clinical practice and research? Faculty Paolo Angeli (Moderator)Guadalupe Garcia-Tsao (Faculty)Valérie Paradis (Faculty)Thomas Reiberger (Faculty)Related episodes EASL Studio S5E5: JHEP Live: the new nomenclature for SLD: a multidisciplinary evaluation and approachEASL...

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead. Faculty Thomas Berg (Moderator)Katie Kelley (Faculty)Daniela Sia...

The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management. Faculty Pierre-Emmanuel Rautou (Moderator)Virginia Hernández-Gea (Faculty)Patrick Kamath (Faculty)Wim Laleman (Faculty)Related episodes: EASL Studio S2E6:...